– More than 55 company-sponsored presentations underscore Biogen
Idec’s commitment to treatment advances for people with MS –
- Company will also launch Registry Research Fellowship Programme -
The collection of data being presented at ECTRIMS represents Biogen Idec’s industry-leading expertise in MS research and showcases the company’s deep understanding of differing patient needs. Through decades of cutting-edge science,
“Biogen Idec is proud to be at the forefront of innovation in MS, which has been made possible through our research and development efforts over the past 30 years,” said
Data at ECTRIMS will be presented from across Biogen Idec’s portfolio, including:
TYSABRI® (natalizumab): offers established efficacy that has been proven to reduce relapses and slow disability progression.
TECFIDERA® (dimethyl fumarate): an oral treatment for relapsing forms of MS, including relapsing-remitting MS (RRMS), which has been clinically proven to significantly reduce important measures of disease activity with a favorable safety/tolerability profile. TECFIDERA is currently approved in
FAMPYRA® (prolonged-release fampridine tablets): the first approved treatment to address the unmet medical need of walking improvement in MS patients, demonstrating efficacy in patients with all MS types. Approved in the
PLEGRIDYTM(pegylated interferon beta-1a): a potential new molecular entity for relapsing forms of MS in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body. Pegylation offers a less-frequent dosing schedule.